Lectin and alternative complement pathway activation in cutaneous manifestations of IgA-vasculitis: A new target for therapy?
Molecular Immunology, vol. 143, pp. 114–121
Abstract
IgA-vasculitis is a systemic small-vessel leucocytoclastic vasculitis and is associated with a high morbidity. The disease can progress to IgA-vasculitis with nephritis (IgAVN) which can result in chronic renal failure. Complement activation is involved in the pathogenesis of IgA-vasculitis. A recent study has shown that cutaneous C3c deposition in IgA-vasculitis is associated with a higher risk to develop IgAVN. In the current study we investigated the different complement pathways that are activated in cutaneous IgA-vasculitis in order to reveal potential targets for intervention. In addition, we analyzed the association of complement factors with IgAVN and the clinical course of the disease. In this retrospective study, the clinicopathological features of 17 patients with IgA-vasculitis were compared with 25 non-IgA-vasculitis cases. Deposition of immunoglobulins and complement was analyzed by direct immunofluorescence for IgA, IgG, IgM, C1q, C4d, properdin, mannan-binding lectin (MBL), ficolin-2 (FCN2), MBL-associated serine protease 1/3 (MASP1/3), MASP2 and C3c. The vascular intensity and positive area was scored on a nominal scale and cumulative score was calculated by multiplying the intensity x area. Properdin was positive in 82% of IgA-vasculitis cases, reflecting alternative pathway activation. C4d was positive in 88% of IgA-vasculitis cases reflecting classical and/or lectin pathway activation, although only 12% of cases were positive for C1q. Lectin pathway activation was demonstrated by deposition of MBL (47%), MASP1/3 (53%) and MASP2 (6%) while FCN2 was found negative. Significantly more deposition of MASP1/3 was found in IgA-vasculitis versus non-IgA-vasculitis. This study demonstrates for the first time activation of lectin and alternative pathways in cutaneous manifestations of IgA-vasculitis. Hence, drugs that intervene in these complement pathways may be an interesting more targeted alternative to the current drugs, in reducing local cutaneous symptoms of the disease, with potentially less side-effects. No association was found between complement activation and IgAVN and/or response to therapy. Therefore, it is unlikely that intervention in complement activation will lead to a better clinical course of the disease.
Authors 5
-
Erasmus MC · Centre for Human Drug Research
Affiliation as printed
Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands; Centre for Human Drug Research, Leiden, The Netherlands. Electronic address: j.damman@erasmusmc.nl
Centre for Human Drug Research, Leiden, The Netherlands
Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
-
Erasmus MC · Centre for Human Drug Research
Affiliation as printed
Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands; Centre for Human Drug Research, Leiden, The Netherlands
Centre for Human Drug Research, Leiden, The Netherlands
Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
-
Erasmus MC · Centre for Human Drug Research
Affiliation as printed
Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands; Centre for Human Drug Research, Leiden, The Netherlands
Centre for Human Drug Research, Leiden, The Netherlands
Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
-
University Medical Center Groningen · Centre for Human Drug Research
Affiliation as printed
Department of Nephrology, University Medical Center Groningen, Groningen, The Netherlands; Centre for Human Drug Research, Leiden, The Netherlands
Centre for Human Drug Research, Leiden, The Netherlands
Department of Nephrology, University Medical Center Groningen, Groningen, The Netherlands
-
Erasmus MC · Centre for Human Drug Research
Affiliation as printed
Department of Dermatology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands; Centre for Human Drug Research, Leiden, The Netherlands
Centre for Human Drug Research, Leiden, The Netherlands
Department of Dermatology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
Cited by 20 stored of 20
20 results
No patents citing this paper on Lens.org (checked 2026-10-11).